Physicians’ Perspectives on Luzinta’s Role in Preventing Retinal Disorders: Insights from a Nationwide Survey

Abstract

Background: Retinal disorders, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and digital vision syndrome (DVS), pose significant challenges globally and in Bangladesh. Luzinta (Lutein USP 20 mg + Zeaxanthin USP 5 mg capsule) has emerged as a potential preventive strategy for these conditions. This study aimed to assess ophthalmologists’ perspectives on Luzinta’s effectiveness, safety, and patient satisfaction in managing retinal disorders.

Methods: This cross-sectional survey was conducted over six months, involving 300 ophthalmologists from urban and rural areas of Bangladesh. A structured questionnaire collected data on preferred conditions for Luzinta use, its perceived benefits, and patient outcomes. Quantitative data were analyzed using descriptive statistics and chi-square tests, while qualitative responses were thematically analyzed.

Results: A majority of respondents (67.33%) preferred Luzinta for managing all three conditions—AMD, DR, and DVS. An overwhelming 91.33% agreed on the necessity of regular supplementation, while 90.10% supported its effectiveness in preventing DR. Patient satisfaction was notably high, with 50.33% reporting "highly satisfied" experiences & 46% reporting “satisfied” experiences. However, only 55.33% of respondents were aware of Luzinta’s anti-inflammatory properties, indicating room for educational improvements.

Conclusion: The study underscores the broad acceptance of Luzinta among Bangladeshi ophthalmologists as a preventive approach for retinal disorders. While patient outcomes and physician confidence in Luzinta are high, targeted awareness initiatives could further enhance its integration into clinical practice. These findings offer valuable insights for retinal care in resource-constrained settings.